MRNS Marinus Pharmaceuticals Inc.

4.92
-0.42  -8%
Previous Close 5.34
Open 5.31
Price To book 11.18
Market Cap 181099419
Shares 36,808,825
Volume 1,825,866
Short Ratio 0.64
Av. Daily Volume 2,164,223

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171107618
  2. 8-K - Current report 171088459
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171088425
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171085769
  5. 8-K - Current report 171078042

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence in 2H 2017.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 data due in 2H 2017.
Ganaxolone
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data released September 11, 2017.
Ganaxolone
CDKL5 disorder